Organophosphate pesticide exposure, PON1, and neurodevelopment in school-age children from the CHAMACOS study

Brenda Eskenazi^{a,*}, Katherine Kogut^a, Karen Huen^a, Kim G. Harley^a, Maryse Bouchard^{a,b}, Asa Bradman^a, Dana Boyd-Barr^c, Caroline Johnson^a, Nina Holland^a

^a Center for Environmental Research and Children's Health, School of Public Health, University of California, 1995 University Avenue, Suite 265, Berkeley, CA 94720-7380, USA

^b CHU Sainte-Justine Research Center and Université de Montréal, Department of Environmental and Occupational Health, Montreal, Quebec, Canada

^c Emory University, Rollins School of Public Health, Atlanta, GA, USA

ARTICLE INFO

Article history:

Received 5 March 2014

Received in revised form

9 June 2014

Accepted 2 July 2014

Available online 27 August 2014

Keywords:

Attention

Conners' Continuous Performance Test (CPT,

KCPT, K-CPT)

Neurodevelopment

Organophosphates

Pesticides

PON1

Wechsler Intelligence Scale for Children

(WISC)

Paraoxonase

ABSTRACT

Introduction: Organophosphate (OP) pesticides remain widely used in agriculture. Previously, we reported that PON1 genotype was directly associated with neurodevelopment at age two, and that PON1 genotype may increase susceptibility to OP exposure.

Objectives: We examined the relationships of maternal and child PON1 genotype and enzyme activity levels and neurodevelopment at school age and examined their interaction with maternal dialkyl phosphate (DAP) metabolite levels to investigate differential susceptibility to OP-related neurotoxicity.

Methods: Participants were from the CHAMACOS longitudinal birth cohort of Latino families in an agricultural region of California. We measured DAP metabolites of OP pesticides in maternal and child urine samples, and analyzed *PON1*₁₉₂ and *PON1*₁₀₈ genotypes and enzyme activity [arylesterase (ARYase), paraoxonase (POase)] in maternal and child blood. We examined their association with children's performance on the Conners' Kiddie Continuous Performance Test (K-CPT) at 5 years ($n=296$) and the Wechsler Intelligence Scale for Children (WISC-IV) at 7 years ($n=327$).

Results: Maternal and child *PON1* genotype was not related to performance on K-CPT or WISC, although WISC scores tended to be lowest in children and children of mothers who carried the *PON1*_{108TT} genotype. Pregnancy ARYase levels were positively associated with all WISC subscales (e.g., 4.0 point increase in Full Scale IQ per standard deviation increase in ARYase, 95% CI=1.6, 6.4), while pregnancy POase levels were positively associated with WISC Processing Speed only. Maternal *PON1*₁₀₈ weakly modified the relationship of maternal DAPS and K-CPT scores ($p_{\text{interaction}}=0.21$) and WISC verbal IQ ($p_{\text{interaction}}=0.71$). The association between DAPs and Full-Scale IQ was strongest for children of mothers with lowest-tertile ARYase levels ($p_{\text{interaction}}=0.27$). This relationship held for both diethyl and dimethyl DAPs and for all subscales of the WISC.

Conclusions: We extend our previous findings that PON1 genotype and enzyme levels may be directly related to performance on certain domains of neurodevelopment in school-age children. Lower maternal PON1 enzyme levels during pregnancy may also increase susceptibility of children to neurotoxicity from OP pesticide exposure.

© 2014 Elsevier Inc. All rights reserved.

Abbreviations: 95% CI, 95% confidence interval; ARYase, arylesterase; CHAMACOS, Center for Health Analysis of Mothers and Children of Salinas; DAP, dialkyl phosphates; DE, diethyl phosphates; DM, dimethyl phosphates; FSIQ, Full Scale Intelligence Quotient; GM, geometric mean; HOME, Home Observation for Measurement of the Environment; HOME-SF, Home Observation for Measurement of the Environment—Short Form; K-CPT, Conners' Continuous Performance Test—Kiddie Version; LOD, limit of detection; n , number (total); nmol/L, nanomoles per liter; OP, organophosphate; POase, paraoxonase; PPVT, Peabody Picture Vocabulary Test; PRI, Perceptual Reasoning Index (WISC-IV); PSI, Processing Speed Index (WISC-IV); SD, standard deviation; TVIP, Test de Vocabulario en Imágenes (PPVT in Spanish); $\mu\text{g/L}$, micrograms per liter; US, United States; VCI, Verbal Comprehension Index (WISC-IV); WISC-IV, Wechsler Intelligence Scale for Children—Fourth Edition; WMI, Working Memory Index (WISC-IV)

* Corresponding author. Fax: +1 510 642 9083.

E-mail address: eskenazi@berkeley.edu (B. Eskenazi).

<http://dx.doi.org/10.1016/j.envres.2014.07.001>

0013-9351/© 2014 Elsevier Inc. All rights reserved.

1. Introduction

Organophosphate (OP) pesticides are widely used in agriculture and until the early 2000 were frequently used for household pest control in the United States (U.S.) (Williams et al., 2008). National biomonitoring efforts indicate that OP pesticide exposure, as measured by the presence of dialkyl phosphate (DAP) metabolites in urine, is nearly ubiquitous in the U.S. population (Barr et al., 2004). Results of exposure modeling (McKone et al., 2007) and organic diet replacement studies (Lu et al., 2008) suggest that diet is a key exposure pathway for adults and children alike.

Two factors that may influence human susceptibility to adverse effects of OP pesticide exposure are genetics and age at time of exposure. The paraoxonase 1 (PON1) enzyme plays an important role in the detoxification and elimination of several oxon derivatives of OP pesticides, thereby preventing the inhibition of acetylcholinesterase (James, 2006; Li et al., 2003). Polymorphisms in the coding (e.g., *PON1*₁₉₂) and promoter (e.g., *PON1*_{−108}) regions of the *PON1* gene have demonstrated particular influence on the production of this detoxifying enzyme. Specifically, individuals with *PON1*_{−108TT} genotype have lower levels of detoxifying enzyme activity than those with *PON1*_{−108CT} or *PON1*_{−108CC} genotypes, suggesting that the CC genotype is the most protective and TT the most vulnerable genotype with regards to susceptibility to OP pesticides (Huen et al., 2010). Similarly, evidence suggests that *PON1*_{192RR} genotype may exert protective influence, whereas QQ genotype may underlie heightened vulnerability to OP pesticides (Huen et al., 2010).

Developmental immaturity may also heighten susceptibility to OP pesticide exposures. Exposures to OP pesticides occur *in utero* as a consequence of ready passage through the placenta and blood-brain barrier (Bradman et al., 2003; Whyatt et al., 2003). In infancy and early childhood, exposure may come through breastmilk (Weldon, 2010), diet, ambient or airborne exposures, or hand-to-mouth activity following contact with contaminated surfaces or house dust (Zartarian et al., 2000). Early life exposure may be particularly detrimental given the rapid and formative brain development occurring during these periods. In addition, children do not have adult level of enzymes to detoxify OP pesticides until after age 7 (Huen et al., 2009a).

We have previously demonstrated associations between women's pregnancy OP pesticide exposure as measured by urinary dialkyl phosphate metabolites (DAPs) and their children's performance on the Bayley Scales of Infant Development at age 2 years (Eskenazi et al., 2007), on measures of attention at age 5 (Marks et al., 2010), and on the Wechsler Intelligence Scale for Children at age 7 (Bouchard et al., 2011). We have also presented evidence that the adverse association between maternal DAPs and Bayley mental development was strongest in children with *PON1*_{−108TT} genotype (Eskenazi et al., 2010). The purpose of the current study is to follow up on our previous research by assessing the potential modifying effects of PON1 genotype and enzyme activity on associations between maternal DAP levels during pregnancy and children's cognitive function and attention at early school age.

2. Materials and methods

2.1. Participants and recruitment

CHAMACOS, which is the acronym for The Center for the Health Assessment of Mothers and Children of Salinas, is a longitudinal birth cohort study aimed at studying the association of pesticides and other environmental exposures with children's health and development. Participants in CHAMACOS are primarily Mexican-American immigrant families residing in the Salinas Valley, an agricultural region of Monterey County, California. Methods for the CHAMACOS study have been described elsewhere (Eskenazi et al., 2004, 2006). Briefly, 1800 pregnant

women were screened for eligibility between October 1999 and 2000 at community clinics serving primarily farmworker families. Eligible women were ≥ 18 years old, < 20 weeks gestation, Spanish- or English-speaking, eligible for Medi-Cal, receiving prenatal care, and planning to deliver at Natividad Medical Center. Of 1130 eligible women, 601 enrolled in the study. We followed 531 of these women to delivery of a liveborn, surviving neonate, and have completed follow-up study visits with families at child ages 6 months and 1, 2, 3.5, 5, and 7 years. All mothers provided written informed consent to participate and, beginning at age seven, children provided verbal assent. The Institutional Review Board at University of California, Berkeley approved this study.

Included in the current analysis are 343 families who participated in either or both of the 5- and 7-year visits for whom PON1 genotype and/or enzyme activity data were available. We excluded from the present analysis 6 twins and 1 child with autism. PON1 genotypes and prenatal enzyme activity and DAP concentrations did not differ significantly between individuals included in this analysis and those lost to follow-up. Compared to mothers lost to follow-up, mothers in this analysis were slightly older at enrollment, were more likely to have lived in the U.S. for 6–10 years at time of enrollment than either less or more time, and were less likely to have smoked during pregnancy. Children in this analysis were less likely to have been born preterm or of low birthweight than their peers who were lost to follow up, but were raised in households with slightly lower home stimulation scores at age 6 months.

2.2. Maternal interviews

Women were interviewed twice during pregnancy (mean=14.0 and 26.6 weeks gestation), shortly after delivery, and at every postnatal visit. Interviews were conducted in Spanish or English by bilingual, bicultural interviewers. At the 6-month postnatal visit, mothers were administered either the Peabody Picture Vocabulary Test (PPVT) (Dunn and Dunn, 1981) or its Spanish equivalent, the Test de Vocabulario en Imágenes Peabody (TVIP) (Dunn et al., 1986), as an indicator of maternal scholastic abilities and general intelligence. At 1, 3.5, and 7 year visits, mothers completed the Center for Epidemiologic Studies Depression Scale (CES-D) (Radloff, 1977). The Home Observation for Measurement of the Environment (HOME) (Caldwell and Bradley, 1984) was completed at 6 months and 1, 2, 3.5, and 7 years; at ages 3.5 and 7, the short form of the HOME scale (HOME-SF) was used (Sugland et al., 1995). Data on family structure and household income were collected at every visit, on child's daycare or school attendance at every postnatal visit, and on children's video game usage at ages 5 and 7 years. Child birthweight was abstracted from medical records by a registered nurse.

2.3. Neurodevelopmental outcomes

Neurodevelopmental assessments were conducted by bilingual, bicultural psychometricians, who were trained and supervised for quality assurance by a clinical neuropsychologist; all were blind to children's pesticide exposures and PON1 genotype or enzyme levels. Assessments were performed in a private room at the CHAMACOS research office or in a recreational vehicle outfitted as a mobile testing facility. We have focused our analyses on two neurodevelopmental outcomes, which we previously found to be related to maternal DAPs, namely, attention at age 5 years and cognition at age 7 years (Marks et al., 2010; Bouchard et al., 2011).

Attention. Children's attention was evaluated at age 5 years using the Conners' Continuous Performance Test—Kiddie Version (K-CPT) (Conners and Staff, 2001), a 7.5-minute computerized vigilance task designed for pre-literate children. The K-CPT presents children with images of familiar objects, which flash briefly and in random succession on the computer screen. Children are instructed to respond to these images by pressing the spacebar as quickly as possible for all images except the ball, and the computer records variables such as response time and errors of omission and commission. For the present analysis, we used the summary Attentional Deficit and Hyperactivity Disorder (ADHD) Confidence Index score, which reflects the degree to which a child's overall pattern of performance corresponds to that of a same-age, same-sex child clinically diagnosed with ADHD (theoretical range=0–100%; 70% would indicate that 70 of 100 children with that performance pattern would be clinically diagnosed as having ADHD).

Cognition. At age 7, children's cognition was assessed in English or Spanish using the Wechsler Intelligence Scale for Children—Fourth Edition (WISC-IV) (Wechsler, 2003). Eight subtests were administered, yielding age-standardized Perceptual Reasoning Index (PRI), Verbal Comprehension Index (VCI), Working Memory Index (WMI), Processing Speed Index (PSI), and Full Scale Intelligence Quotient (FSIQ) scores (mean 100, SD 15 for each).

2.4. Pesticide exposure measurement

We measured six non-specific DAP metabolites in maternal urine collected twice during pregnancy, typically at the time of the prenatal interviews. Urine

specimens were immediately aliquotted and stored at -80°C until shipment on dry ice to the Centers for Disease Control and Prevention. DAP metabolites were measured using gas chromatography-tandem mass spectrometry and quantified using isotope dilution calibration (Bravo et al., 2002). These DAP metabolites were comprised of three dimethyl (DM) phosphate metabolites (dimethylphosphate, dimethylthiophosphate, dimethyldithiophosphate) and three diethyl (DE) phosphate metabolites (diethylphosphate, diethylthiophosphate, and diethyldithiophosphate) (Bradman et al., 2005). Details of urine collection, analysis, and quality control procedures, including detection limits and use of blanks and spikes, have been described elsewhere (Bradman et al., 2005).

Concentrations below the limit of detection (LOD) were randomly imputed based on a log-normal probability distribution, estimated using maximum likelihood estimation, and molar concentrations were summed to yield total DM, total DE, and total DAP concentrations (nmoles/L).

2.5. *PON1* genotype and enzyme measurements

We collected maternal blood during pregnancy (mean 26.7, $\text{SD} \pm 2.8$ weeks), fetal umbilical cord blood, and child blood samples at 5 years of age. Heparinized whole blood was collected in BD vacutainers[®] (Becton, Dickinson and Company, Franklin Lakes, NJ), centrifuged, divided into plasma, buffy coats and red blood cells, and stored at -80°C . Serum and blood clots were collected in vacutainers containing no anticoagulant.

Maternal and child genotyping was conducted using DNA isolated from blood clots as previously described (Holland et al., 2006). The coding polymorphism, *PON1*₁₉₂, was genotyped using the Taqman real-time PCR method (Eskenazi et al., 2010; Holland et al., 2006). We used a two-part nested PCR strategy to genotype the promoter SNP *PON1*_{−108}. The region surrounding the SNP was pre-amplified using non-allelic flanking primers and then the amplicon was diluted and used as the template for the subsequent Amplifluor assay.

PON1 enzyme activity levels were measured in heparinized plasma. The *PON1* enzyme activities towards phenyl acetate (ARYase) and paraoxon (POase) were determined using spectrophotometric methods as described by Huen et al. (2009b). The ARYase assay provides an indirect measure of *PON1* enzyme quantity that is strongly correlated with other ELISA and Western blot-based methods of *PON1* quantitation (Connelly et al., 2008; Kujiraoka et al., 2000) and is genetically influenced by the promoter polymorphism *PON1*_{−108}. In contrast, the measure of POase from the substrate-specific assay is reflective both of quantity and catalytic efficiency of the *PON1* enzyme and is primarily affected by the coding polymorphism *PON1*₁₉₂. Quality assurance of genotype and enzyme activity data are detailed elsewhere (Huen et al., 2009b).

2.6. Data analysis

We first determined whether *PON1* genotype (maternal and child) or enzyme activity (maternal, cord, and child) had a direct association with the neurodevelopmental outcomes of interest, controlling for maternal DAP levels and other covariates. We then examined the effect modification of *PON1* genotype and enzyme activity on the previously reported (Marks et al., 2010; Bouchard et al., 2011) relationship between exposure as measured by maternal DAPs and neurodevelopment (attention and cognition).

Total DAP, DM, and DE metabolite concentrations, including mean pregnancy concentrations, were transformed to the log10 scale and analyzed as continuous variables. *PON1*₁₉₂ and *PON1*_{−108} genotypes were analyzed primarily as indicator variables, with the non-susceptible genotypes (e.g., *PON1*_{192RR} and *PON1*_{−108CC}) as the respective reference groups. In separate analyses, *PON1* genotypes were analyzed as discrete numerical variables reflecting the number of susceptible alleles (0, 1, 2). *PON1* enzyme activity was also analyzed primarily as indicator variables, with ARYase and POase values at each time point categorized as tertiles and with the lowest tertile as the reference group, though in separate analyses, ARYase and POase were analyzed as continuous values (standard deviation units). K-CPT ADHD Confidence Index percentage scores were analyzed as a censored continuous variables, and WISC outcome variables were analyzed as continuous variables.

To maintain consistency with our previous publications, we controlled for all covariates identified in the papers examining the relation of maternal DAP levels and child attention (Marks et al., 2010) and cognition (Bouchard et al., 2011), though we added one new covariate to attention analyses: video game usage at age 5 years. Thus, age 5 attention (K-CPT) scores were adjusted for psychometrician; child sex and age at testing (continuous months); maternal education at enrollment (categorical), PPVT score at 6 months post-partum (continuous), and CES-D depression status at 3.5 years post-partum (dichotomous; ≥ 16 symptom points versus fewer); and child's duration of breastfeeding (continuous months), time in childcare between ages 3.5 and 5 (dichotomous; 15+ hours in out-of-home care versus less), and video game usage at age 5 (dichotomous any versus none). For the measures of WISC performance at age 7 years, we controlled for maternal education at enrollment (categorical), maternal PPVT score at 6 months post-partum (continuous), and HOME score at 6 months (continuous), and for VCIQ and FSIQ analyses, we also controlled for language of assessment (dichotomous English

versus Spanish). In addition, all analyses assessing ARYase adjusted for the individual's *PON1*₁₉₂ genotype as a comprehensive measure of *PON1* status; pregnancy ARYase analyses adjusted for maternal *PON1*₁₉₂ genotype while cord blood and child age 5 ARYase analyses adjusted for child *PON1*₁₉₂ genotype. *PON1* status accounts for both *PON1* catalytic efficiency and enzyme quantity and can be more informative than looking at *PON1* genotype alone in epidemiologic studies (Richter and Furlong, 1999).

We tested for effect modification by maternal or child *PON1* genotype on the association between average prenatal DAP levels and neurodevelopmental outcomes. We also assessed effect modification by maternal and child enzyme levels using maternal enzyme levels and DAPs in specimens collected at ~ 26 weeks gestation or child enzyme levels in cord blood and average maternal prenatal DAPs. This allowed us to assess “real-time” interactions between individuals' OP exposure at a given point in time and the enzymes they had available to detoxify these exposures. We constructed separate linear regression models within each genotype or enzyme level category (i.e. low, medium, high tertiles). This allowed for a visual comparison of associations between maternal DAP metabolite levels and neurodevelopmental outcome under different genotype or gene activity conditions. We tested the statistical significance of interactions using both categorical and continuous interaction terms. Interaction was assessed for categorical variables as follows: we constructed linear regression models which each included two interaction terms per model (e.g., $\text{ARYase}_{\text{Medium}} * \text{DAP}$ and $\text{ARYase}_{\text{High}} * \text{DAP}$ versus the reference, $\text{ARYase}_{\text{Low}} * \text{DAP}$), and the interaction *p*-value was calculated using a post-estimation combined *F*-test (or chi-square test) for the two interaction variables. To assess interaction based on continuous variables, we constructed parallel linear regression models using discrete numerical genotype (0, 1, 2) or continuous enzyme activity (standard deviation units) and a single continuous interaction term (e.g. $\text{ARYase}_{\text{SD}} * \text{DAP}$), and report the *p*-value for that interaction term. Statistical significance for interactions was based on a *p*-value of 0.15. Data analyses were completed using Stata version 11.2 software (StataCorp, 2009).

3. Results

At the time of pregnancy enrollment, mothers averaged 26.7 years of age ($\text{SD}=5.2$) with 86% having been born in Mexico, and 79% having less than a high school education. Almost all lived within 200% of poverty (Table 1). Only 4% of children were born at < 2500 g and 7% were born at < 37 weeks (data not shown). Children were assessed on average (mean $\pm$ standard deviation (SD)) at 5.0 ± 0.2 years, and 7.1 ± 0.2 years. Approximately two-thirds of the children were tested in Spanish at age 7 years.

The children averaged 45.9% ($\text{SD}=17.5$) on the Confidence Index of the K-CPT at 5 years, with 8.4% of children scoring above a 70%. The mean WISC Full-Scale IQ was 103.8 ($\text{SD}=14.3$) at 7 years (Supplementary Table 1). The geometric mean (GM) (95% Confidence Interval, CI) of the average total DAP, DM and DE concentrations in maternal urine during pregnancy was 123.5 nmoles/L (110.3, 238.3), 90.8 nmoles/L (79.7, 103.3) and 18.4 nmoles/L (16.1, 21.0), respectively (Supplementary Table 2). Average prenatal urinary DAP concentrations in this population are higher than general U.S. population levels (Bradman et al., 2005).

We found that 24.6% of children had the *PON1*_{192QQ} genotype, 23.4% had *PON1*_{192RR}, and the remainder were heterozygous (see Table 2). For *PON1*_{−108}, 30.2% had *PON1*_{−108CC} and 18.6% had *PON1*_{−108TT}, and the remainder was heterozygous. Supplementary Table 3 presents the descriptive statistics for ARYase and POase levels in the maternal blood, cord blood, and child blood at age 5 years, which confirm our previous reports (Huen et al., 2010) of lowest enzyme activity levels in cord blood, followed by child age 5 and adult maternal blood (ARYase GM=30.6, 80.5, and 124.5 U/mL, respectively; POase GM=195.4, 602.5, and 728.9 U/L, respectively). As in previous analyses (Huen et al., 2010), ARYase and POase levels varied widely by genotype; mothers and children with *PON1*_{108TT} and *PON1*_{192RR} genotype tended to have the lowest ARYase levels, and mothers and children with *PON1*_{108TT} but with *PON1*_{192QQ} genotype had the lowest POase levels (not shown).

The ARYase and POase levels in maternal blood ($r=0.26$, $p<0.001$), cord blood ($r=0.59$, $p<0.001$) and 5-year old blood ($r=0.23$, $p<0.001$) were weakly to moderately positively correlated (Supplementary Table 4). ARYase levels in cord and in 5-year

Table 1
Sociodemographic characteristics of the CHAMACOS cohort (n=343).

	N	(%)
Child's sex		
Male	165	(48.1)
Female	178	(51.9)
Maternal country of birth		
Mexico	295	(86.0)
U.S.	43	(12.5)
Other	5	(1.5)
Maternal age at baseline		
18–24	145	(42.3)
25–29	114	(33.2)
30–34	55	(16.0)
35–45	29	(8.5)
Marital status at baseline		
Married/living as married	280	(81.6)
Not married	63	(18.4)
Poverty level during pregnancy ^a		
< Poverty level	213	(62.1)
Within 200% of poverty level	118	(34.4)
> 200% of poverty level	12	(3.5)
Maternal education		
< 6th grade	152	(44.3)
7th–12th grade	119	(34.7)
Completed high school	72	(21.0)
Maternal intelligence (PPVT Score)		
≤ 74	112	(32.7)
75–99	123	(35.9)
≥ 100	108	(31.5)
HOME score at 6 months		
≤ 31.0	145	(42.3)
31.1–33.3	89	(26.0)
≥ 33.4	109	(31.8)
Language of age 7 WISC testing		
English	107	(32.7)
Spanish	220	(67.3)

^a U.S. Census Bureau Year 2000 poverty thresholds based on household income and number of people supported.

blood ($r=0.52$, $p<0.001$) and POase in cord and in 5-year blood ($r=0.76$, $p<0.001$) were strongly correlated. Maternal pregnancy ARYase levels were poorly correlated with fetal ($r=-0.01$, $p=0.94$) and weakly correlated with child levels of ARYase ($r=0.25$, $p=0.005$); maternal POase levels were weakly to moderately correlated with both fetal ($r=0.29$, $p<0.001$) and child POase ($r=0.42$, $p<0.001$) levels.

In Table 2, we examine the main effect of maternal and child genotype on child's performance on the K-CPT and WISC IQ and show no clear association of maternal or child *PON1*₁₉₂ genotype with either attention or cognition. Child IQ scores tended to be lowest in mothers and in children with the *PON1*–108TT genotype, though this trend was not statistically significant. Children of mothers with *PON1*–108CT and *PON1*–108TT genotypes also showed higher (i.e. worse) K-CPT scores, though this trend was also not statistically significant. In Table 3, we examine the main effect of maternal and child enzyme activity on child neurodevelopment. We observe no association of POase levels and performance on the K-CPT or the WISC IQ, except for a positive relationship of POase levels in pregnancy and the Processing Speed Index at age 7 ($\beta=2.6$ per standard deviation increase in enzyme levels, 95% CI=0.2, 5.0), and a borderline-significant negative (i.e. protective) relationship of POase levels in pregnancy and the age 5 ADHD Confidence Index score ($\beta=-2.8$ per standard deviation increase in enzyme levels, 95% CI=–5.7, 0.1). In contrast, ARYase levels in pregnancy were positively associated with all subscales on the

WISC. Specifically, a standard deviation increase in maternal ARYase levels during pregnancy was related to a 3.9 point increase in Perceptual Reasoning (95% CI=1.4, 6.4), 2.6 points increase in Verbal Comprehension (95% CI=0.5, 4.6), a 3.6 point increase in Working Memory (95% CI=1.3, 5.9), a 2.1 point increase in Processing Speed (95% CI=–0.4, 4.5), and an overall 4.0 point increase in Full Scale IQ (95% CI=1.6, 6.4) in the children at 7 years. The associations between ARYase levels in cord or child age 5 blood and IQ, though positive, were usually less strong. For example, only the relationship between cord blood ARYase levels and age 7 Processing Speed ($\beta=1.9$, 95% CI=0.1, 3.8) and between age 5 ARYase levels and Verbal Comprehension ($\beta=2.3$, 95% CI=0.3, 4.2) and Processing Speed ($\beta=1.8$, 95% CI=0.8, 3.6) were statistically significant (Table 3). ADHD Confidence index was somewhat associated with ARYase levels in cord blood ARYase levels ($\beta=-2.1$ per standard deviation increase in enzyme levels, 95% CI=–4.6, 0.3).

We next investigated whether maternal or child genotype modified the relationship of maternal DAP levels during pregnancy and performance on the K-CPT (Marks et al. 2010) and WISC IQ (Bouchard et al. 2011). Overall, we found weak evidence of effect modification on K-CPT performance and WISC IQ. Specifically, children of mothers carrying the T allele of *PON*–108 showed a positive relationship (i.e. poorer attention) of DAPS and ADHD Confidence Index (*PON*–108CT $\beta=5.9$, 95% CI=–1.2, 13.0; *PON*–108CT $\beta=5.9$, 95% CI=–3.3, 15.2) whereas children of mothers with *PON*–108CC did not ($\beta=-4.7$, 95% CI=–14.0, 4.5; $p_{\text{interaction}}=0.21$ categorical). Among WISC scales, most notably we found that a 10-fold increase in maternal total DAP levels during pregnancy was associated with an 8.3 point decrease in the child's Verbal Comprehension Index (95% CI=–15.7, –1.0) among mothers with *PON1*–108TT genotype, a 4.9 point decrease (95% CI=–9.3, –0.5) among heterozygous mothers, and a 3.2 decrease (95% CI=–11.5, 5.1) among mothers with *PON1*–108CC genotype, although the p -value for interaction was not significant ($p_{\text{interaction}}=0.71$ categorical) (Table 4). This difference in association by maternal genotype was primarily with maternal DM DAP concentration. We found similar suggestive evidence by child genotype (Supplementary Table 5).

Next, we considered whether maternal ARYase and POase levels during pregnancy modified the relationship of DAP levels in prenatal urine samples with child K-CPT and WISC IQ scores. There was no clear pattern of effect modification on K-CPT. However, the inverse associations of DAPs and Full-Scale IQ were most pronounced for children whose mothers had the lowest ARYase levels and absent in those with the highest. Specifically, we observed a 10.9 point decrease (95% CI=–19.7, –2.0) for lowest-, a 5.3 point decrease (95% CI=–14.2, 3.6) for middle-, and a 0.9 point increase (95% CI=–7.6, 9.4) for highest-tertile ARYase, respectively, though the interaction was not statistically significant ($p_{\text{interaction}}=0.27$ categorical) (Fig. 1; Supplementary Table 6). For all WISC subscales, a similar pattern was observed with the strongest inverse association between maternal DAP levels and WISC performance in children of mothers with lowest-tertile ARYase levels, but the only statistically-significant association was seen for Verbal Comprehension ($\beta=-9.2$, 95% CI=–17.3, –1.1). This trend usually held for both DM and DE metabolites but was more consistent for DM metabolites. Though there was some evidence of interaction between both total DAPs and DMs and POase levels on WISC subscales, the greatest deficits were usually seen in offspring of mothers with middle-tertile POase levels. As shown in Supplementary Table 7, the relationship between prenatal average maternal DAPs, DMs and DEs and attention and IQ usually showed the greatest decrements in those with the lowest levels of cord ARYase levels; however, the interactions were not significant and the trend is less clear than for maternal ARYase

Table 2
Adjusted association between maternal and child genotype and measures of child attention at age 5 on the Kiddie Continuous Performance test (K-CPT) and cognition at age 7 on the Wechsler Intelligence Scale for Children-IV (WISC).

Genotype	Gene frequencies		Age 5			Age 7																				
	N	(%)	KCPT ADHD index ^a		p	WISC PRI ^b		p	WISC VCI ^c		p	WISC WMI ^b		p	WISC PSI ^b		p	WISC FSIQ ^c		p						
			β	(95% CI)		trend ^d	β		(95% CI)	trend ^d		β	(95% CI)		trend ^d	β		(95% CI)	trend ^d		β	(95% CI)	trend ^d	β	(95% CI)	trend ^d
Mother																										
<i>PON1</i> ₁₀₈																										
CC	92	(28.4)		Reference	0.41		Reference	0.69		Reference	0.22		Reference	0.37		Reference	0.32		Reference	0.28						
CT	156	(48.1)	2.9	(−1.9, 7.8)		−2.6	(−6.8, 1.6)		−0.2	(−3.8, 3.3)		0.6	(−3.1, 4.4)		0.8	(−2.9, 4.5)		−0.5	(−4.3, 3.3)							
TT	76	(23.5)	2.1	(−3.6, 7.9)		−0.8	(−5.8, 4.2)		−2.8	(−7.0, 1.5)		−2.2	(−6.6, 2.3)		−2.4	(−6.8, 2.0)		−2.5	(−7.0, 1.9)							
<i>PON1</i> ₁₉₂																										
RR	93	(28.6)		Reference	0.86		Reference	0.65		Reference	0.29		Reference	0.30		Reference	0.72		Reference	0.54						
QR	144	(44.3)	2.1	(−2.9, 7.1)		−2.6	(−7.0, 1.7)		0.2	(−3.5, 3.9)		−0.3	(−4.2,3.6)		−0.2	(−4.0, 3.7)		−0.9	(−4.8, 3.0)							
QQ	88	(27.1)	−0.5	(−6.1, 5.1)		1.0	(−3.7, 5.8)		2.1	(−1.9, 6.2)		2.3	(−2.1,6.6)		−0.8	(−5.0, 3.5)		1.3	(−3.0, 5.6)							
Child																										
<i>PON1</i> ₁₀₈																										
CC	99	(30.2)		Reference	0.88		Reference	0.52		Reference	0.27		Reference	0.94		Reference	0.28		Reference	0.41						
CT	168	(51.2)	−0.2	(−4.9, 4.6)		−0.5	(−4.6, 3.6)		0.5	(−3.0, 4.0)		0.5	(−3.1,4.1)		−2.1	(−5.6, 1.5)		0.0	(−3.7, 3.7)							
TT	61	(18.6)	0.6	(−5.4, 6.5)		−1.8	(−7.0, 3.4)		−2.9	(−7.3, 1.5)		−0.3	(−4.9, 4.3)		−2.2	(−6.8, 2.3)		−2.2	(−6.8, 2.5)							
<i>PON1</i> ₁₉₂																										
RR	77	(23.4)		Reference	0.96		Reference	0.21		Reference	0.68		Reference	0.69		Reference	0.36		Reference	0.70						
QR	171	(52.0)	5.0	(0.1, 9.9)*		−4.6	(−9.0, −0.2)**		0.8	(−2.9, 4.6)		−4.2	(−8.1, −0.3)**		−4.8	(−8.5, −1.0)**		−4.7	(−8.6, −0.8)**							
QQ	81	(24.6)	0.1	(−5.8, 5.9)		−3.4	(−8.5, 1.7)		−0.9	(−5.3, 3.5)		0.7	(−3.8, 5.3)		1.9	(−2.5, 6.2)		−1.0	(−5.6, 3.6)							

^a Adjusted for mean prenatal total DAPs; psychometrician; child sex and age at testing; maternal education, PPVT, and depression; duration of breastfeeding; time in childcare; and video game usage.

^b Adjusted for mean prenatal total DAPs, maternal education, maternal PPVT, HOME score at 6 months of age, and language of neurological assessment at 7 years of age.

^c Adjusted for mean prenatal total DAPs, maternal education, maternal PPVT, HOME score at 6 months of age, and language of neurological assessment at 7 years of age.

^d *p*-value on trend based on discrete variable representing the number (0, 1, 2) of protective alleles (C for *PON1*₁₀₈, R for *PON1*₁₉₂).

* *p* < 0.10.

** *p* < 0.05.

Table 3
Adjusted association of arylesterase (ARYase) and paraoxonase (POase) enzyme activity level (per SD increase) with measures of attention at age 5 on the Kiddie-Continuous Performance test (K-CPT) and cognition at age 7 on the Wechsler Intelligence Scale for Children-IV (WISC), CHAMACOS.

	Age 5		Age 7									
	KCPT ADHD Index ^b		WISC PRI ^c		WISC VCI ^d		WISC WMI ^c		WISC PSI ^c		WISC FSIQ ^d	
	β	(95% CI)	β	(95% CI)	β	(95% CI)	β	(95% CI)	β	(95% CI)	β	(95% CI)
ARYase^a												
Pregnancy	−0.5	(−3.6, 2.7)	3.9	(1.4, 6.4)**	2.6	(0.5, 4.6)**	3.6	(1.3, 5.9)**	2.1	(−0.4, 4.5)*	4.0	(1.6, 6.4)**
Cord blood	−2.1	(−4.6, 0.3)*	0.1	(−2.0, 2.3)	0.2	(−1.7, 2.2)	1.1	(−0.8, 2.9)	1.9	(0.1, 3.8)**	0.1	(−1.0, 2.9)
Child age 5	−1.1	(−3.4, 1.3)	0.7	(−1.6, 3.0)	2.3	(0.3, 4.2)**	1.1	(−1.0, 3.1)	1.8	(0.8, 3.6)**	1.6	(−0.5, 3.7)
POase												
Pregnancy	−2.8	(−5.7, 0.1)*	1.1	(−1.3, 3.5)	0.4	(−1.6, 2.3)	1.0	(−1.3, 3.3)	2.6	(0.2, 5.0)**	1.2	(−1.3, 3.7)
Cord blood	−0.9	(−3.3, 1.5)	−0.1	(−2.3, 2.2)	−0.1	(−2.1, 1.8)	1.2	(−0.6, 3.0)	1.0	(−0.9, 2.8)	0.9	(−1.1, 2.8)
Child age 5	1.5	(−0.7, 3.7)	0.4	(−1.8, 2.7)	0.9	(−1.0, 2.8)	0.0	(−1.9, 2.0)	−0.6	(−2.3, 1.1)	0.3	(−1.7, 2.3)

^a All ARYase analyses adjusted for individual's PON1₁₉₂ genotype (maternal genotype for pregnancy, child genotype for cord blood and age 5) in addition to other specified covariates.

^b Adjusted for mean prenatal total DAPs (pregnancy, cord blood) or age 5 total DAPS (age 5); psychometrician; child sex and age at testing; maternal education, PPVT, and depression; duration of breastfeeding; time in childcare; and video game usage.

^c Adjusted for mean prenatal total DAPs (pregnancy, cord blood) or age 5 total DAPS (age 5), maternal education, maternal PPVT, and HOME score at 6 months of age.

^d Adjusted for mean prenatal total DAPs (pregnancy, cord blood) or age 5 total DAPS (age 5), maternal education, maternal PPVT, HOME score at 6 months of age, and language of neurological assessment at 7 years of age.

* $p < 0.10$.

** $p < 0.05$.

levels. For cord POase levels, the greatest IQ decrements were often observed in children with the highest level of POase.

4. Discussion

We have previously reported that prenatal exposure to OP pesticides as measured by maternal DAP levels was negatively associated with attention and cognition in school-age children (Marks et al., 2010; Bouchard et al., 2011). We now present evidence that this association with IQ is strongest in children whose mothers had the lowest levels of PON1 ARYase enzyme activity during pregnancy.

When the children were two years old, we found a relationship between DAPs and the Mental Development Index (MDI) and, to a lesser extent, the Psychomotor Development Index (PDI) on the Bayley Scales (Eskenazi et al., 2007). We also reported a main effect relationship of child PON1₁₀₈ with MDI and PDI test performance. However, maternal and child PON1₁₉₂ genotype and ARYase and POase in maternal, cord, and child blood were not related to MDI or PDI, though children of mothers within the highest-tertile ARYase did have the highest MDI scores. Although interactions were not significant, the relationship between DAPs and mental development was strongest in toddlers with PON1_{108TT} polymorphism; results were similar albeit muted by maternal genotype. In addition, the relationship of DAP levels and MDI was strongest in children within the lowest tertiles of cord ARYase and POase, although there was no clear pattern across tertiles; again, results were similar but weaker for maternal levels.

In the present study, we examined these associations between DAPs, PON1 and neurobehavioral development when the children reached school-age. Although we continue to observe a relationship between maternal pregnancy DAP levels and child neurobehavioral deficits, the relationship between maternal and child PON1₁₀₈ genotype and neurodevelopment was weaker than at the younger ages. We find only limited evidence that child or maternal PON1₁₀₈ genotype modifies the relation of DAP levels and neurodevelopment. However, at this older age, enzyme activity, in particular ARYase, appears to have a more important main effect than genotype on neurodevelopment and to show somewhat stronger evidence of effect modification. We note that

ARYase level is a measure of the enzyme quantity that is influenced by the PON1₁₀₈ promoter polymorphism. We found that the relationship between ARYase enzyme activity in maternal blood during pregnancy and IQ is stronger than that for child enzyme activity.

The differences in results between toddler and school age in CHAMACOS children can be attributed to a number of factors: (1) not all the same children were assessed at these intervals; (2) we used different tools to assess development at these ages, and though the WISC and Bayley scales may both assess cognition and other higher cortical functions, the Bayley scales are not strongly predictive of school age IQ (Bornstein and Colombo, 2012; McGrath et al., 2004); and (3) neurobehavioral developmental functioning is multifactorial and has numerous known and unknown determinants, of which PON1 genotype and enzyme activity represent only one factor. Nevertheless, we find that PON1 genotype and/or enzyme activity seem to be directly related to cognitive functioning and may modify to some extent the association of OP pesticide exposure as measured by urinary DAPs and neurodevelopment.

To our knowledge, only one other study has examined the effect modification of PON on neurodevelopment. Engel et al. (2011) reported that in 6- to 9-year-olds, increasing DAP levels, and in particular increasing DM levels, were associated with decreases in Full Scale IQ (not significant) and Perceptual Reasoning IQ, but only in children of mothers carrying the PON1_{192QQ} genotype. They did not detect any effect modification by PON1 enzyme activity and concluded that perhaps genotype was a more stable long-term predictor of metabolism potential. However, we have previously reported great variability in expression of genotype, with a very wide range of enzyme activity among people with the same genotype (Huen et al., 2010; Furlong et al., 2006).

Differences between our study and the study by Engel et al. may be due to racial/ethnic and other genetic differences in the two populations. In addition, both studies used nonspecific urinary metabolites (DAPS) to assess exposure to OP pesticides, and these metabolites derive from multiple parent compounds (CDC 2010) that may vary in the degree to which they interact with PON1 and influence neurodevelopment. The pesticides contributing to the DAP levels and their relative toxicities may vary considerably between the CHAMACOS agricultural population and the urban

Table 4Adjusted associations of average maternal prenatal dialkyl phosphate metabolites (DAPs) and neurodevelopment outcomes at ages 5 and 7, stratified by **maternal** *PON1*_{–108} and *PON1*_{–192} genotype, CHAMACOS.

Maternal genotype	Age 5			Age 7			Age 5			Age 7			Age 5			Age 7		
	KCPT ADHD index ^a		p-value	WISC PRI ^b		p-value	WISC VCI ^c		p-value	WISC WMI ^b		p-value	WISC PSI ^b		p-value	WISC FSIQ ^c		p-value
	β	(95% CI)	interaction ^{d,e}	β	(95% CI)	interaction ^{d,e}	β	(95% CI)	interaction ^{d,e}	β	(95% CI)	interaction ^{d,e}	β	(95% CI)	interaction ^{d,e}	β	(95% CI)	interaction ^{d,e}
Total DAPs																		
PON1 _{−108}																		
CC	−4.7	(−14.0, 4.5)	0.21 ^d	−1.0	(−10.2, 8.1)	0.74	−3.2	(−11.5, 5.1)	0.71	−1.5	(−9.3, 6.2)	0.67	−4.2	(−11.5, 3.1)	0.96	−3.0	(−11.4, 5.3)	0.76
CT	5.9	(−1.2,13.0)	0.25 ^e	−3.9	(−8.8, 0.9)	0.97	−4.9	(−9.3, −0.5) ^{**}	0.41	−5.1	(−10.0, −0.2) ^{**}	0.42	−3.7	(−8.4, 1.0)	0.99	−6.1	(−10.5, −1.7) ^{**}	0.66
TT	5.9	(−3.3, 15.2)		−2.5	(−13.0, 8.0)		−8.3	(−15.7, −1.0) ^{**}		−3.6	(−11.3, 4.1)		−2.3	(−10.7,6.0)		−5.0	(−13.8, 3.9)	
PON1 ₁₉₂																		
RR	2.8	(−6.5, 12.2)	0.92	−2.7	(−10.5, 5.2)	0.88	−5.6	(−13.2, 2.0)	0.88	−2.3	(−8.3, 3.7)	0.49	−5.8	(−13.2, 1.7)	0.71	−5.3	(−12.7, 2.0)	0.96
QR	5.1	(−1.6, 11.8)	0.87	−4.4	(−10.7, 1.9)	0.95	−4.1	(−9.3, 1.0)	0.95	−2.7	(−8.2, 2.8)	0.29	−2.0	(−7.4, 3.3)	0.52	−4.3	(−9.6, 0.9)	0.99
QQ	3.7	(−6.0, 13.4)		−1.9	(−9.5, 5.8)		−4.0	(−9.7, 1.6)		−5.9	(−13.3, 1.6)		−1.8	(−8.3, 4.7)		−4.1	(−10.9, 2.7)	
Dimethyl DAPs																		
PON1 _{−108}																		
CC	−4.1	(−11.9, 3.8)	0.22	−1.7	(−9.9, 6.6)	0.79	−3.2	(−10.6, 4.3)	0.65	−2.4	(−9.3, 4.6)	0.65	−0.4	(−7.0, 6.3)	0.64	−2.6	(−10.1, 5.0)	0.69
CT	5.3	(−1.2, 11.7)	0.33	−3.3	(−7.7, 1.1)	0.94	−4.3	(−8.3, −0.3) ^{**}	0.38	−4.6	(−9.0, −0.1) ^{**}	0.35	−2.7	(−7.0, 1.6)	0.52	−5.1	(−9.0, −1.1) ^{**}	0.47
TT	2.6	(−5.4, 10.7)		−2.1	(−11.3, 7.1)		−7.9	(−14.3, −1.5) ^{**}		−4.7	(−11.3, 1.9)		−1.7	(−9.0, 5.5)		−5.2	(−12.9, 2.5)	
PON1 ₁₉₂																		
RR	2.0	(−6.4, 10.3)	0.76	−2.8	(−10.0, 4.4)	0.88	−5.4	(−12.3, 1.6)	0.88	−2.2	(−7.7, 3.4)	0.58	−4.2	(−11.2, 2.8)	0.60	−4.8	(−11.6, 2.1)	0.91
QR	4.5	(−1.4, 10.4)	0.73	−3.4	(−9.1, 2.3)	0.87	−3.9	(−8.6, 0.8)	0.84	−3.0	(−8.0, 2.0)	0.31	0.1	(−4.7, 5.0)	0.66	−3.4	(−8.1, 1.4)	0.89
QQ	1.9	(−6.8, 10.7)		−1.0	(−7.7, 5.8)		−3.6	(−8.7, 1.4)		−5.3	(−11.9, 1.3)		−1.2	(−6.9, 4.6)		−3.3	(−9.3, 2.7)	
Diethyl DAPs																		
PON1 _{−108}																		
CC	−2.3	(−12.2, 7.6)	0.55	0.5	(−7.6, 8.5)	0.76	0.9	(−6.5, 8.2)	0.54	0.9	(−5.8, 7.5)	0.71	−7.0	(−13.1, −0.9)	0.49	−0.8	(−7.9, 6.3)	0.56
CT	3.0	(−3.4, 9.4)	0.60	−2.1	(−6.9, 2.7)	0.65	−3.6	(−7.9, 0.6) [*]	0.69	−1.3	(−6.1, 3.5)	0.70	−2.5	(−7.0, 2.0)	0.42	−4.0	(−8.3, 0.2) [*]	0.73
TT	4.5	(−2.9, 11.9)		−0.3	(−9.3, 8.7)		−1.5	(−8.1, 5.0)		4.3	(−2.4, 10.9)		−2.9	(−10.1, 4.3)		0.8	(−7.0, 8.7)	
PON1 ₁₉₂																		
RR	5.0	(−3.4, 13.5)	0.53	−2.9	(−10.1, 4.3)	0.995	−3.8	(−10.8, 3.2)	0.56	−4.3	(−9.6, 1.1)	0.18	−7.0	(−13.5, −0.5) ^{**}	0.40	−5.9	(−12.5, 0.7) [*]	0.60
QR	−0.5	(−6.3, 5.4)	0.96	−2.4	(−7.8, 3.0)	0.99	−0.9	(−5.4, 3.6)	0.999	2.7	(−2.0, 7.4)	0.69	−2.7	(−7.2, 1.9)	0.24	−1.8	(−6.3, 2.7)	0.73
QQ	4.6	(−4.6, 13.8)		−1.4	(−9.1, 6.2)		−1.7	(−7.5, 4.1)		−0.2	(−7.8, 7.3)		−1.9	(−8.3, 4.5)		−1.8	(−8.6, 5.0)	

^a Adjusted for psychometrician; child sex and age at testing; maternal education, PPVT, and depression; duration of breastfeeding; time in childcare; and video game usage.^b Adjusted for maternal education, maternal PPVT, HOME score at 6 months of age, and language of neurological assessment at 7 years of age.^c Adjusted for maternal education, maternal PPVT, HOME score at 6 months of age, and language of neurological assessment at 7 years of age.^d Interaction *p*-value based on categorical interaction terms; a postestimation combined F-test (or chi-square test) was used to test the two genotype*DAPs interaction terms (e.g. *PON108CT* × DAPs and *PON108TT* × DAPs versus *PON108CC* × DAPs).^e Interaction *p*-value based on continuous interaction terms.* *p* < 0.10.** *p* < 0.05.

Fig. 1. Association between maternal prenatal (26-week) total DAP concentration (log10 scale) and child age 7 WISC IQ scores as modified by maternal 26-week arylesterase activity.

New York City population of the study by Engel et al., and DM levels were considerably higher in the CHAMACOS population (Bradman et al., 2005; Wolff et al., 2007).

PON1 is a multifactorial enzyme and it is not clear exactly how it may interact with OPs to modify their relationship with neurodevelopment. Although our key hypothesized mechanism was that PON1 genotype and enzyme activity would affect the individual's abilities to detoxify the potentially neurotoxic OP pesticides, PON1's function of protecting individuals from oxidative stress may play an equally, if not more important, role on neurodevelopmental function. The fact that our results, in many cases, seem stronger for DM levels supports this hypothesis, since DEs but not DMs are derived from known PON1 substrates (e.g., chlorpyrifos-oxon and diazoxon). Furthermore, other OP pesticides not hydrolyzed by PON1, such as malathion, which devolves to DM DAPs, have been shown to induce oxidative stress (Durak et al., 2009; Franco et al., 2009).

Our research is limited in a number of ways. Despite the large sample size, this study lacked power for examining interaction by genotype or enzyme concentrations. We have limited our analysis to only two main *PON1* polymorphisms; although there are other polymorphisms associated with ARYase and POase activity in this cohort, they are in strong linkage disequilibrium with those we examined here (Huen et al., 2011). It is also possible that genetic variants in other genes from related pathways (e.g. cholinesterase) could be involved. In addition, DAP metabolites are an imperfect measure of OP pesticide exposure given the short half-life of OP pesticides in the body and environment, the variability in exposure over time, the potential for exposure to preformed DAPs in the environment (Quirós-Alcalá et al., 2012), and differences in metabolism that may affect excretion (Wessels et al., 2003). It is not clear whether DAP metabolite levels differ as a function of PON status, even among individuals with similar environmental exposures. We have previously reported that whereas mothers with lowest- and middle-tertile ARYase levels showed positive, albeit non-significant, relationships between plasma levels of diazinon and chlorpyrifos and urinary levels of DE metabolites, for mothers with highest-tertile ARYase levels, there was an inverse association between these parent compounds in plasma and urinary DE metabolites (Huen et al., 2012). Lastly, our results may not be generalizable given this unique cohort of primarily Mexican American children. *PON1* allelic distributions are known to vary by ethnic/racial groups (Huen et al., 2011; Chen et al., 2003; Rojas-García et al., 2005), although the relationship between genotype and enzyme activities appears to be comparable (Costa et al., 2005).

In summary, in this follow-up study of Mexican–American children in the CHAMACOS cohort, we extend previous findings of associations between *PON1* genotype and enzyme levels and certain domains of neurodevelopment through early school age, presenting new evidence that adverse associations between DAP levels and IQ may be strongest in children of mothers with the lowest levels of *PON1* enzyme. Future policies regarding protection from OP pesticide exposure should consider that some children may be more vulnerable to early life exposures by virtue of their or their mother's genetic predispositions and resulting *PON1* enzyme activity.

Grant information

This publication was made possible by research supported by grant numbers R82670901, RD 83171001, and RD-83273401 from the United States Environmental Protection Agency (EPA) and PO1 ES009605, R01 ES012503, and R01 ES023067-01A1 from the United States National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS, NIOSH, NIH or EPA.

Acknowledgments

We acknowledge the CHAMACOS staff, students, community partners, and the CHAMACOS participants and families, without whom this study would not be possible. None of the authors has a competing financial interest.

Appendix A. Supplementary materials

Supplementary data associated with this article can be found in the online version at <http://dx.doi.org/10.1016/j.envres.2014.07.001>.

References

- Barr, D., Bravo, R., Weerasekera, G., Calabiano, L., Whitehead, R., 2004. Concentrations of dialkyl phosphate metabolites of organophosphorus pesticides in the U.S. population. *Environ. Health Perspect.* 112 (2), 186–200.
- Bornstein, M.H., Colombo, J., 2012. Infant cognitive functioning and child mental development. In: Pauen, S., Bornstein, M. (Eds.), *Early Childhood Development and Later Achievement*. Cambridge University Press, New York, pp. 118–147.

- Bouchard, M.F., Chevrier, J., Harley, K.G., Kogut, K., Vedar, M., Calderon, N., et al., 2011. Prenatal exposure to organophosphate pesticides and iq in 7-year-old children. *Environ. Health Perspect.* 119 (8), 1189–1195.
- Bradman, A., Barr, D.B., Claus Henn, B.G., Drumheller, T., Curry, C., Eskenazi, B., 2003. Measurement of pesticides and other toxicants in amniotic fluid as a potential biomarker of prenatal exposure: a validation study. *Environ. Health Perspect.* 111 (14), 1779–1782.
- Bradman, A., Eskenazi, B., Barr, D., Bravo, R., Castorina, R., Chevrier, J., et al., 2005. Organophosphate urinary metabolite levels during pregnancy and after delivery in women living in an agricultural community. *Environ. Health Perspect.* 113 (12), 1802–1807.
- Bravo, R., Driskell, W.J., Whitehead Jr., R.D., Needham, L.L., Barr, D.B., 2002. Quantitation of dialkyl phosphate metabolites of organophosphate pesticides in human urine using GC–MS–MS with isotopic internal standards. *J. Anal. Toxicol.* 26 (5), 245–252.
- Caldwell, B., Bradley, R., 1984. *Home Observation For Measurement Of The Environment*. University of Arkansas, Little Rock, AR.
- Chen, J., Kumar, M., Chan, W., Berkowitz, G., Wetmur, J.G., 2003. Increased influence of genetic variation on PON1 activity in neonates. *Environ. Health Perspect.* 111 (11), 1403–1409.
- Connelly, P.W., Maguire, G.F., Picardo, C.M., Teiber, J.F., Draganov, D., 2008. Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. *J. Lipid Res.* 49 (1), 245–250.
- Conners, C.K., Staff, M., 2001. *Conners' Kiddie Continuous Performance Test (K-CPT): Computer Program for Windows Technical Guide and Software Manual*. MHS, Toronto, ON.
- Costa, L.G., Cole, T.B., Vitalone, A., Furlong, C.E., 2005. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. *Clin. Chim. Acta* 352 (1–2), 37–47.
- Dunn, L., Dunn, L., 1981. *Peabody Picture Vocabulary Test, Revised*. American Guidance Service, Circle Pines, MN.
- Dunn, L., Padilla, E., Lugo, D., Dunn, L., 1986. *Test de Vocabulario en Imágenes Peabody: Adaptación Hispanoamericana (Peabody Picture Vocabulary Test: Hispanic-American Adaptation)*. Dunn Educational Services, Inc, Circle Pines, MN.
- Durak, D., Uzun, F.G., Kalender, S., Ogtucu, A., Uzunhisarcikli, M., Kalender, Y., 2009. Malathion-induced oxidative stress in human erythrocytes and the protective effect of vitamins C and E in vitro. *Environ. Toxicol.* 24 (3), 235–242.
- Engel, S.M., Wetmur, J., Chen, J., Zhu, C., Barr, D.B., Canfield, R.L., et al., 2011. Prenatal exposure to organophosphates, paraoxonase 1, and cognitive development in childhood. *Environ. Health Perspect.* 119 (8), 1182–1188.
- Eskenazi, B., Harley, K., Bradman, A., Weltzien, E., Jewell, N.P., Barr, D.B., et al., 2004. Association of in utero organophosphate pesticide exposure and fetal growth and length of gestation in an agricultural population. *Environ. Health Perspect.* 112 (10), 1116–1124.
- Eskenazi, B., Huen, K., Marks, A., Harley, K.G., Bradman, A., Barr, D.B., et al., 2010. PON1 and neurodevelopment in children from the CHAMACOS study exposed to organophosphate pesticides in utero. *Environ. Health Perspect.* 118 (12), 1775–1781.
- Eskenazi, B., Marks, A.R., Bradman, A., Fenster, L., Johnson, C., Barr, D.B., et al., 2006. In utero exposure to dichlorodiphenyltrichloroethane (DDT) and dichlorodiphenyldichloroethylene (DDE) and neurodevelopment among young Mexican American children. *Pediatrics* 118 (1), 233–241.
- Eskenazi, B., Marks, A.R., Bradman, A., Harley, K., Barr, D.B., Johnson, C., et al., 2007. Organophosphate pesticide exposure and neurodevelopment in young Mexican–American children. *Environ. Health Perspect.* 115 (5), 792–798.
- Franco, J.L., Posser, T., Mattos, J.J., Trevisan, R., Brocardo, P.S., Rodrigues, A.L., et al., 2009. Zinc reverses malathion-induced impairment in antioxidant defenses. *Toxicol. Lett.* 187 (3), 137–143.
- Furlong, C.E., Holland, N., Richter, R.J., Bradman, A., Ho, A., Eskenazi, B., 2006. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. *Pharmacogenet Genomics* 16 (3), 183–190.
- Holland, N., Furlong, C., Bastaki, M., Richter, R., Bradman, A., Huen, K., et al., 2006. Paraoxonase polymorphisms, haplotypes, and enzyme activity in latino mothers and newborns. *Environ. Health Perspect.* 114 (7), 985–991.
- Huen, K., Barcellos, L., Beckman, K., Rose, S., Eskenazi, B., Holland, N., 2011. Effects of PON polymorphisms and haplotypes on molecular phenotype in Mexican–American mothers and children. *Environ. Mol. Mutagen.* 52 (2), 105–116.
- Huen, K., Bradman, A., Harley, K., Yousefi, P., Boyd Barr, D., Eskenazi, B., et al., 2012. Organophosphate pesticide levels in blood and urine of women and newborns living in an agricultural community. *Environ. Res.* 117, 8–16.
- Huen, K., Harley, K., Bradman, A., Eskenazi, B., Holland, N., 2010. Longitudinal changes in PON1 enzymatic activities in Mexican–American mothers and children with different genotypes and haplotypes. *Toxicol. Appl. Pharmacol.* 244 (2), 181–189.
- Huen, K., Harley, K., Brooks, J., Hubbard, A., Bradman, A., Eskenazi, B., et al., 2009a. Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphisms. *Environ. Health Perspect.* 117 (10), 1632–1638.
- Huen, K., Richter, R., Furlong, C., Eskenazi, B., Holland, N., 2009b. Validation of PON1 enzyme activity assays for longitudinal studies. *Clin. Chim. Acta* 402 (1–2), 67–74.
- James, R.W., 2006. A long and winding road: defining the biological role and clinical importance of paraoxonases. *Clin. Chem. Lab. Med.* 44 (9), 1052–1059.
- Kujiraoka, T., Oka, T., Ishihara, M., Egashira, T., Fujioka, T., Saito, E., et al., 2000. A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. *J. Lipid Res.* 41 (8), 1358–1363.
- Li, H.L., Liu, D.P., Liang, C.C., 2003. Paraoxonase gene polymorphisms, oxidative stress, and diseases. *J. Mol. Med. (Berl.)* 81 (12), 766–779.
- Lu, C., Barr, D.B., Pearson, M.A., Waller, L.A., 2008. Dietary intake and its contribution to longitudinal organophosphorus pesticide exposure in urban/suburban children. *Environ. Health Perspect.* 116 (4), 537–542.
- Marks, A.R., Harley, K., Bradman, A., Kogut, K., Barr, D.B., Johnson, C., et al., 2010. Organophosphate pesticide exposure and attention in young Mexican–American children: the CHAMACOS study. *Environ. Health Perspect.* 118 (12), 1768–1774.
- McGrath, E., Wypij, D., Rappaport, L.A., Newburger, J.W., Bellinger, D.C., 2004. Prediction of IQ and achievement at age 8 years from neurodevelopmental status at age 1 year in children with D-transposition of the great arteries. *Pediatrics* 114 (5), e572–e576.
- McKone, T.E., Castorina, R., Harnly, M.E., Kuwabara, Y., Eskenazi, B., Bradman, A., 2007. Merging models and biomonitoring data to characterize sources and pathways of human exposure to organophosphorus pesticides in the Salinas Valley of California. *Environ. Sci. Technol.* 41 (9), 3233–3240.
- Quirós-Alcalá, L., Bradman, A., Smith, K., Veerasekera, G., Odetokun, M., Barr, D.B., et al., 2012. Organophosphorous pesticide breakdown products in house dust and children's urine. *J. Expo. Sci. Environ. Epidemiol.* 22 (6), 559–568.
- Radloff, L., 1977. The CES-D scale: a self-report depression scale for research in the general population. *Appl. Psychol. Meas.* 1 (3), 385–401.
- Richter, R.J., Furlong, C.E., 1999. Determination of paraoxonase (PON1) status requires more than genotyping. *Pharmacogenetics* 9 (6), 745–753.
- Rojas-García, A.E., Solís-Heredia, M.J., Pina-Guzmán, B., Vega, L., López-Carrillo, L., Quintanilla-Vega, B., 2005. Genetic polymorphisms and activity of PON1 in a Mexican population. *Toxicol. Appl. Pharmacol.* 205 (3), 282–289.
- Stata Corporation, 2009. *Stata Statistical Software: Release*. Stata Corp LP, College Station, TX p. 11.
- Sugland, B.W., Zaslav, M., Smith, J.R., Brooks-Gunn, J., Coates, D., Blumenthal, C., et al., 1995. The early childhood home inventory and home-short form in differing racial/ethnic groups. *J. Fam. Issues* 16 (5), 632–663.
- Wechsler, D., 2003. *Wechsler Intelligence Scale for Children—Fourth Edition (WISC-IV) Administration and Scoring Manual*. Harcourt Assessment Incorporated, San Antonio, TX.
- Weldon, R.H., 2010. *Biomonitoring Persistent and Non-persistent Chemicals in Human Breast Milk and Endocrine Disruption of Lactation*. University of California, Berkeley, Berkeley.
- Wessels, D., Barr, D.B., Mendola, P., 2003. Use of biomarkers to indicate exposure of children to organophosphate pesticides: implications for a longitudinal study of children's environmental health. *Environ. Health Perspect.* 111 (16), 1939–1946.
- Whyatt, R.M., Barr, D.B., Camann, D.E., Kinney, P.L., Barr, J.R., Andrews, H.F., et al., 2003. Contemporary-use pesticides in personal air samples during pregnancy and blood samples at delivery among urban minority mothers and newborns. *Environ. Health Perspect.* 111 (5), 749–756.
- Williams, M.K., Rundle, A., Holmes, D., Reyes, M., Hoepner, L.A., Barr, D.B., et al., 2008. Changes in pest infestation levels, self-reported pesticide use, and permethrin exposure during pregnancy after the 2000–2001 U.S. Environmental Protection Agency restriction of organophosphates. *Environ. Health Perspect.* 116 (12), 1681–1688.
- Wolff, M.S., Engel, S., Berkowitz, G., Teitelbaum, S., Siskind, J., Barr, D.B., et al., 2007. Prenatal pesticide and PCB exposures and birth outcomes. *Pediatr. Res.* 61 (2), 243–250.
- Zartarian, V.G., Ozkaynak, H., Burke, J.M., Zufall, M.J., Rigas, M.L., Furtaw Jr., E.J., 2000. A modeling framework for estimating children's residential exposure and dose to chlorpyrifos via dermal residue contact and nondietary ingestion. *Environ. Health Perspect.* 108 (6), 505–514.